Statements (49)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
benzodiazepine |
| gptkbp:ATCCode |
N05BA04
|
| gptkbp:CASNumber |
1088-11-5
|
| gptkbp:category |
sedative
muscle relaxant hypnotic chloroarene GABAA receptor positive allosteric modulator lactam |
| gptkbp:chemicalFormula |
C15H11ClN2O
|
| gptkbp:discoveredBy |
1960s
|
| gptkbp:eliminationHalfLife |
36–200 hours
|
| gptkbp:hasInChIKey |
GOLCXWZKUVPXAZ-UHFFFAOYSA-N
|
| gptkbp:hasSMILES |
C1C(=O)NC2=C(C=C(C=C2)Cl)C(=N1)C3=CC=CC=C3
|
| https://www.w3.org/2000/01/rdf-schema#label |
Nordazepam
|
| gptkbp:IUPACName |
7-chloro-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one
|
| gptkbp:KEGGID |
D02797
|
| gptkbp:legalStatus |
Schedule IV (US)
Prescription only (various countries) |
| gptkbp:mechanismOfAction |
positive allosteric modulator of GABAA receptor
|
| gptkbp:meltingPoint |
239–240 °C
|
| gptkbp:metabolite_of |
gptkb:diazepam
gptkb:chlordiazepoxide clorazepate medazepam prazepam |
| gptkbp:molecularWeight |
270.72 g/mol
|
| gptkbp:pregnancyCategory |
D (US)
|
| gptkbp:PubChem_CID |
4379
CHEMBL1201191 4538 DB01579 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
confusion
muscle weakness drowsiness ataxia |
| gptkbp:synonym |
gptkb:nordiazepam
calmday desmethyldiazepam madar nordazep stilny |
| gptkbp:UNII |
U5A3O8V2FQ
|
| gptkbp:usedFor |
treatment of insomnia
treatment of anxiety |
| gptkbp:bfsParent |
gptkb:N05BA
|
| gptkbp:bfsLayer |
7
|